Susquehanna Portfolio Strategies
CLYM icon

Susquehanna Portfolio Strategies’s Climb Bio CLYM Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Hold
11,056
– – ﹤0.01% 806
2026
Q1 		$75.7K Buy
+11,056
New +$63.8K ﹤0.01% 942
2025
Q4 		– Sell
-18,272
Closed -$36.7K – 1155
2025
Q3 		$36.7K Buy
+18,272
New +$33.9K ﹤0.01% 1025

Other funds holding CLYM

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna Portfolio Strategies's CLYM Position: Q2 2026 in Review

Susquehanna Portfolio Strategies held its Climb Bio (CLYM) position steady in Q2 2026 at 11,056 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #806.

Susquehanna Portfolio Strategies first reported a position in CLYM in Q3 2025 and has held it in 3 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Susquehanna Portfolio Strategies held 11,056 shares of Climb Bio worth $144K as of Q2 2026.
  • Susquehanna Portfolio Strategies left its Climb Bio share count unchanged in Q2 2026.
  • Climb Bio made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #806 holding.
  • Susquehanna Portfolio Strategies first reported a position in Climb Bio in Q3 2025 and has held it in 3 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.